Overview of Phosphorus Effect in Molybdenum-Based Hydrotreating Catalysts Supported on Ordered Mesoporous Siliceous Materials

This chapter presents an overview of the literature on the effect of phosphorus modification of ordered mesoporous silica (OMS) such as MCM-41, HMS, SBA-15, and SBA-16 to be used as supports for hydrotreating catalysts based on transition metal sulfides (TMS). The influence of the support modification with variable quantities of phosphorus on the performance for hydrodesulfurization (HDS) and hydrodenitrogenation (HDN) reactions is outlined and discussed considering the changes in the structural and textural properties (SBET), acidity, reducibility, etc., of the substrate brought about by phosphorus incorporation

Sulfided NiMo/<em>Clinoptilolite</em> Catalysts for Selective Sulfur Removal from Naphtha Stream without Olefin Hydrogenation

The natural clinoptilolite zeolite has been modified by acid leaching with HNO3 in order to obtain economic material for supporting NiMoS hydrotreating catalysts. The most optimized zeolite material was obtained by leaching with HNO3 at 80°C during 24 h. The bimetallic NiMo catalysts prepared by wet impregnation of a zeolite support, followed by calcination and sulfidation, were characterized by several physico-chemical techniques and tested in the hydrodesulfurization (HDS) of 3-methyl-thiophene (3-MT) model feed at atmospheric H2 pressure and T = 280°C. For all catalysts, the 3-MT transformation mainly occurs via direct desulfurization reaction route being diminished the catalyst hydrogenation function. This was linked with the formation of highly stacked layers of MoS2 particles having a low amount of “brim sites,” as demonstrated by HRTEM. The cause of the best performance of Ni-Mo(H)/Z-1 sulfide catalyst in the HDS of 3-MT can be the presence of K+ impurities on the support surface which forces the formation of highly stacked layers of MoS2 particles

Environmental and socioeconomic determinants of heart failure

Background: Over 1.5 million people in Poland suffer from heart failure (HF). The risk of hospitalization is related to environmental, socioeconomic factors and the organization of the health care system. Aims: The study aimed to assess the influence of environmental and socioeconomic factors on the prevalence of hospitalization for HF. Methods: The impact of environmental and socioeconomic factors on HF hospitalizations in Poland in 2012–2019 based on the National Institute of Public Health and Central Statistical Office in Poland data and panel data regression techniques has been estimated. Results: There were 1,618,734 HF-related hospitalizations (51.3% male; 82.6% aged &gt;65 years). An increase in the number of physicians by 10/10000 population and healthcare expenditure of 100 PLN per capita resulted in 3.5% (–0.035; 95% confidence interval [CI], –0.06–[–0.01]; P = 0.002) and 3% (–0.029; 95% CI, –0.04–[–0.013]; P &lt;0.001) decrease in hospitalizations, respectively. For each new outpatient healthcare facility per 10 000 population, there was a 3% (–0.031; 95% CI, –0.048–[–0.014]; P &lt;0.001) decrease in hospitalizations. One percentage point increase in the proportion of green areas resulted in a 2.7% (–0.027; 95% CI, –0.042–[–0.01]; P = 0.049) decrease in hospitalizations. However, an increase of cars by 1000 inhabitants and a 1 percentage point increase in the unemployment rate were associated with a 6% increase in HF hospitalizations (0.064; 95% CI, 0.008–0.121; P = 0.026). Conclusions: The number of HF-related hospitalizations has been increasing in the last decade. This trend is most noticeable in regions with low socioeconomic development and poor medical facilities. Our study indicates that health policy measures including environmental and socioeconomic instruments may result in positive health outcomes. Additional analyzes are needed to compare the impact of socioeconomic and environmental factors against the impact of healthcare alone

Defining the Critical Hurdles in Cancer Immunotherapy

ABSTRACT: Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators, others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet be overcome to improve outcomes of patients with cancer

Defining the critical hurdles in cancer immunotherapy

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer

Petrographic composition of lignite from the Szczerców deposit, Polish Lowlands

Macroscopic and microscopic composition of lignite from the Szczerców deposit belonging to the Bełchatów Lignite Mine (Polish Lowlands) has been examined. The macroscopic composition was determined according to the newest lithological classification of humic coal. On this basis, it has been shown that the main lithotypes occurring in the Szczerców deposit are the detritic and xylodetritic lignites

Hydrodesulfurization of Dibenzothiophene over Ni-Mo-W Sulfide Catalysts Supported on Sol-Gel Al₂O₃-CeO₂

To achieve sulfur content in gas oil at a near-zero level, new catalysts with improved hydrogenation functions are needed. In this work, new Ni-Mo-Mo hydrodesulfurization (HDS) catalysts supported by Al2O3-CeO2 materials were synthesized to evaluate their efficiency in the reaction of HDS with dibenzothiophene (DBT). Al2O3-CeO2 supports different CeO2 loadings (0, 5, 10 and 15 wt.%) and supported NiMoW catalysts were synthesized by sol-gel and impregnation methods, respectively. The physicochemical properties of the supports and catalysts were determined by a variety of techniques (chemical analysis, XRD, N2 physisorption, DRS UV-Vis, XPS, and HRTEM). In the DBT HDS reaction carried out in a batch reactor at 320 °C and a H2 pressure of 5.5 MPa, the sulfide catalysts showed a dramatic increase in activity with increasing CeO2 content in the support. Nearly complete DBT conversion (97%) and enhanced hydrogenation function (HYD) were achieved on the catalyst with the highest CeO2 loading. The improved DBT conversion and selectivity towards the hydrogenation products (HYD/DDS ratio = 1.6) of this catalyst were attributed to the combination of the following causes: (i) the positive effect of CeO2 in forcing the formation of the onion-shaped Mo(W)S2 layers with a large number of active phases, (ii) the inhibition of the formation of the undesired NiAlO4 spinel phase, (iii) the appropriate textural properties, (iv) the additional ability for heterolytic dissociation of H2 on the CeO2 surfaces, and (v) the increase in Brønsted acidity

Catalysts for the Conversion of CO2 to Low Molecular Weight Olefins—A Review

There is a large worldwide demand for light olefins (C2=–C4=), which are needed for the production of high value-added chemicals and plastics. Light olefins can be produced by petroleum processing, direct/indirect conversion of synthesis gas (CO + H2) and hydrogenation of CO2. Among these methods, catalytic hydrogenation of CO2 is the most recently studied because it could contribute to alleviating CO2 emissions into the atmosphere. However, due to thermodynamic reasons, the design of catalysts for the selective production of light olefins from CO2 presents different challenges. In this regard, the recent progress in the synthesis of nanomaterials with well-controlled morphologies and active phase dispersion has opened new perspectives for the production of light olefins. In this review, recent advances in catalyst design are presented, with emphasis on catalysts operating through the modified Fischer–Tropsch pathway. The advantages and disadvantages of olefin production from CO2 via CO or methanol-mediated reaction routes were analyzed, as well as the prospects for the design of a single catalyst for direct olefin production. Conclusions were drawn on the prospect of a new catalyst design for the production of light olefins from CO2